June 20, 2007 — A large, international clinical trial in teens with schizophrenia demonstrated that the atypical antipsychotic aripiprazole (Abilify, Otsuka Pharmaceutical Co and Bristol-Myers Squibb) ...
PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. today announced the launch of ABILIFY® (aripiprazole) Injection, an injectable ...
Data from Phase 3 Trial demonstrated improvement in time to relapse, the primary efficacy endpoint, for patients receiving once-monthly aripiprazole IM depot formulation compared to placebo Results ...
Physicians Expect Use of Seroquel XR and Abilify to Increase Over the Next Two Years, According to a New Report from Decision Resources BURLINGTON, Mass., Nov. 16, 2010 /PRNewswire/ -- Decision ...
TOKYO, JAPAN & PRINCETON, NEW JERSEY, FEBRUARY 29 -- Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) ...
PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd., announced today that the U.S. Food and Drug Administration (FDA) has approved ...
Our recommendations for dosage and administration of aripiprazole in patients experiencing schizophrenia are in agreement with the manufacturer's prescribing information. However, the optimal dose has ...
The committee reviewed the data available on the clinical and cost effectiveness of aripiprazole, having considered evidence on the nature of schizophrenia in people aged 15 to 17 years and the value ...
In adults with major depressive disorder, adding aripiprazole to antidepressant therapy (ADT) resulted in significant improvement in the primary endpoint, the Montgomery-Asberg Depression Rating Scale ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results